// App-Quantinova.ai

P419 : Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: Pooled Analysis from ULTRA 1 and ULTRA 2

Researchers

Presenter

  • W.J. Sandborn

Principal Investigators

  • J. Petersson

  • B. Pappalardo

  • A.M. Robinson

  • A. Lazar

  • Q. Zhou

  • R.B. Thakkar

  • J.-F. Colombel

  • W. Reinisch

  • S. Vermeire

Medical Centers

  • McMaster University, Gastroenterology, Hamilton, Canada

  • Medical University of Vienna, Dept. for Gastroenterology and Hepatology, Vienna, AustriaAbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United StatesAbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • Univeristy of California San Diego, Division of Gastroenterolgy, San Diego, United States

  • Northwestern University Feinberg School of Medicine, Digestive Health Centre, Chicago, United States

  • University Hospital CHU of Liege, Gastroenterology, Liege, Belgium

Locations

  • United States

  • Canada

  • Germany

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Infectious Diseases (ID)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

Biomarkers

  • Hematocrit

  • High sensitivity C-reactive protein

  • Human albumin

  • Red Blood Cells

Drug/Treatment

  • Adalimumab

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved